We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 29, 2020

Activity of Lurbinectedin in Second-Line Small Cell Lung Cancer Patients Who Are Candidates for Re-Challenge With First-Line Treatment

Lung Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Antitumor Activity of Lurbinectedin in Second-Line Small Cell Lung Cancer Patients Who Are Candidates for Re-Challenge With the First-Line Treatment
Lung Cancer 2020 Dec 01;150(xx)90-96, V Subbiah, L Paz-Ares, B Besse, V Moreno, S Peters, MA Sala, JA López-Vilariño, C Fernández, C Kahatt, V Alfaro, M Siguero, A Zeaiter, K Zaman, R López, S Ponce, V Boni, J Arrondeau, JP Delord, M Martínez, L Wannesson, A Antón, J Valdivia, A Awada, R Kristeleit, ME Olmedo, MJ Rubio, J Sarantopoulos, SP Chawla, J Mosquera-Martinez, M D' Arcangelo, A Santoro, VM Villalobos, J Sands, J Trigo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading